

1 Abstract

2  
3 Peri /postmenopausal endometriosis is not as rare as once we thought. Accumulated data revealed  
4 that around 1/3-1/4 of women with surgically-diagnosed endometriosis after the age of 40. The  
5 uneasiness of the issue of malignant transformation or malignancy in such women created a challenge  
6 for us. Here the management strategy for women with endometriosis after the age of 40 is discussed  
7 in the light of scientific evidence.  
8

9 **Key words:** Endometriosis, perimenopause, menopause, endometriosis associated ovarian  
10 cancer (EAOC), Pain, Infertility  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

PEER REVIEW COPY  
Minerva Medica

## INTRODUCTION

Endometriosis is defined as the presence of endometrial tissue outside the uterus. It is one of the most peculiar diseases in medicine; we still do not know how it happens, what its course is during the years, whether it will inhibit fertility or -as recently gained much focus on- it will cause malignant disease. Since estrogen plays a central role in endometriosis, for many years it has been thought that "endometriosis is the disease of fertile years". With the accumulation of data, we have realized that "there is no age limit" for endometriosis. However, the management of endometriosis differs according to the age due to changing "demands" of the patient and "concerns" of the medical professional.

Endometriosis at older ages is clinical challenge especially for those at menopausal transition. In 1993, attention was especially drawn to perimenopausal women for by Witt and Barad (1). Thereafter there have been some reports mainly case reports and case series, a few reviews and few clinical studies on peri and postmenopausal endometriosis.

Here we aimed to review the "challenging" management of women with endometriosis after the age of 40 in the light of available data.

### **Endometriosis is not "limited to" reproductive ages**

Endometriosis is a common gynecological disease and its prevalence is about 1 in 10 women. Although it is well known that estrogen is sine-qua-non for endometriosis, it may be found at any age of a woman. The first report on postmenopausal endometriosis was a case report of 78-year-old woman by Edgar Haydn in 1942(2). According to big-series of Haas et al, (3), of total 42,079 women histologically proven endometriosis, there were 13,985 patients (33.23 %) in the perimenopausal age group (40–50 years), and 2,984 (7.09 %) patients in the postmenopausal age group(50–95 years). In another study from Ireland, of 1383 women surgically proven endometriosis, the proportion of cases after the age of 40 is 27.4% (4). It was also shown that for the age 40 and above, the age-specific incidence has been increased in years (4). Thus perhaps it may be assumed that when the awareness increases, the diagnosis and incidence of endometriosis after the age of 40 may be increased with time. In our study (Oral E et al, submitted), we have found that endometrioma was the most common benign adnexial mass among 1100 women at the age 40 and above. According to the literature, prevalence of postmenopausal endometriosis is about 2-5% (5).

### **Confronting the problems in women with endometriosis after the age of 40**

#### *Is menopause at earlier age?*

According to scarce available data, both surgery for endometriomas and also endometriosis per se may opt women to have earlier menopause (6). Thus, although the onset of menopause at the age 40-45 and before 40 are accepted as early menopause and premature menopause, respectively, these are not uncommon among women with endometriosis especially with a history of infertility (7).

#### *Fertility issues*

Since women anticipate high level carrier in contemporary lifestyle, usually fertility is postponed until the ages of late 30s and early 40s. Thus, especially in women with endometriosis may be obliged to

1 face the fertility problems mainly due to low ovarian reserve. Apart from the endometriosis itself,  
2 concomitant problems such as adenomyosis and myoma may contribute to fertility problem (figure 1).  
3 We ironically call this as “dragon’s triangle”.  
4

#### 5 6 7 *Pain*

8 Pain is one of the major symptoms in endometriosis. Although decreasing estrogen levels in older ages  
9 may alleviate this symptom, peripheral or local production of estrogens as well as external estrogens  
10 such as hormonal treatments may cause exacerbation of the symptom even in women who had radical  
11 surgery for endometriosis. Pain persistence or recurrence are important problems even at age >40.  
12 According to 72 postmenopausal women (age 46-79) with endometriosis from a single institution, one  
13 of the two most common symptoms at presentation was abdominal pain (26.4%) (8).  
14  
15

#### 16 17 18 *Malignancy issue*

19 The first report on malignant transformation of the endometriotic tissue was described by Sampson in  
20 1925 (9). For last couple of years, malignancies especially ovarian carcinoma associated with or  
21 stemmed from endometriosis gained much attention. It is now accepted that malignant  
22 transformation of endometriosis occurs -mostly in the ovaries- in 1-3% cases (10). The continuum to  
23 malignancy of ovarian carcinoma from atypical endometriosis has been unveiled in years since the first  
24 report of 5 cases (three clear cell carcinomas, two endometrioid carcinomas) in 1988 by LaGrenade  
25 and Silverberg (11,12). Significant increase in the relative risk (RR) of clear cell (RR: 3.37, CI: 1.24-9.14),  
26 and endometrioid type (RR: 2.53, CI: 1.19-5.38) ovarian carcinoma has been reported in women with  
27 endometrioma after at least 5 years from the diagnosis (13). There is some evidence that such  
28 malignant transformation occurs during the perimenopausal period (14). Moreover, in a recent report,  
29 Murakami et al. (15) searched the cases of ovarian carcinoma stemmed from endometriotic cyst in the  
30 literature starting from year 2000. They have found that the median time from the diagnosis of the  
31 cyst to diagnosis of the carcinoma was 36 months and they have bravely suggested that when the cyst  
32 was found it might already have the malignant cells in it.  
33  
34

35  
36 Although there is still no definite marker to confirm or exclude malignancy, for women with  
37 suspicion of malignancy, human epididymal secretory protein (HE4) is important, especially  
38 combined with CA-125 as ROMA index is accepted as the most efficient biomarker today (16).  
39  
40

41  
42 In our retrospective analysis we have also drawn attention to the probable continuum of the  
43 pathological way from endometriosis to atypical endometriosis and ovarian carcinoma. Of 661  
44 women with ovarian carcinoma or borderline ovarian tumor, 48 (4.7%) had endometriosis and  
45 of those 48, 73% had atypical endometriosis (17). Recently we have also found Endometrioma-  
46 associated ovarian tumors were developed in nearly 11% of women with endometrioma (Oral  
47 E et al, submitted). The risk of ovarian cancer is especially higher in women with longstanding  
48 (more than 10 years) endometriosis, or recurrent endometrioma, newly diagnosed  
49 endometrioma (10).  
50  
51

#### 52 53 *Menopausal Symptoms* 54 55

1 Women with endometriosis may have an inauguration of menopause by medical or surgical  
2 means. In addition, usually they tend to have earlier spontaneous menopause as mentioned  
3 above. These facts may lead to abrupt fall in the estrogen levels and cause severe menopausal  
4 symptoms(18). Thus, this is important problem especially when we consider women with  
5 endometriosis after the age of 40.  
6  
7

### 8 **Management of fertility problems in women with endometriosis after the age of 40**

9  
10 Endometriosis is a cause of subfertility via different suggested mechanisms such as diminished  
11 ovarian reserve, poor oocyte quality, tubal problems, fertilization and implantation problems  
12 even sperm problems (19-21). For women over 40 years of age, diminished ovarian reserve  
13 seems to be utmost important. It is known that age, previous surgery for endometrioma and  
14 also endometrioma per se are important factors may contribute to diminished ovarian reserve  
15 in such women. Though management should include IVF for women over 40, the first step  
16 should be ovarian reserve testing so that deciding whether to perform embryo pooling or not.  
17 After having the embryos frozen, ovarian suppression by GnRH-analogs should be commenced  
18 followed by frozen-thawed embryo transfer (figure 2).  
19  
20  
21  
22

### 23 **Management of pain problems in women with endometriosis after the age of 40**

24  
25 Management of pain in women with endometriosis over 40 is again dependent on fertility  
26 desire. If so, women are to be offered IVF treatment. If pain is the only complaint surgery is to  
27 be the first management option due to the risk of malignant transformation and malignancy  
28 (Figure 3).  
29  
30

31 If there is medical (eg. cardiovascular disease, pulmonary disease etc.) or surgical (previous  
32 multiple operations) contraindications for a surgical approach and there is no sign for  
33 malignancy, then medical treatment is to be considered. According to data we have at the  
34 moment there are many medical options for treatment of endometriosis, basically;  
35 Gonadotropin releasing hormone agonists (GnRH-a), Progestogens, or Aromatase Inhibitors  
36 (AIs), Gonadotropin releasing hormone antagonists (GnRH-ant), combined oral contraceptives  
37 (COCs), Levonorgestrel intrauterin system(LNG-IUS) can be used for women with  
38 endometriosis after the age 40.  
39  
40  
41  
42  
43

### 44 **Management of Menopausal symptoms in women with endometriosis after the age of 40**

45  
46 When the women with endometriosis do have menopausal symptoms, there may be two  
47 concerns on each pan of the scale; one is basic menopausal concerns (bones, brain,  
48 cardiovascular system, and quality of life especially in terms of vasomotor and vulvo-vaginal  
49 problems) and the second one is the risk of recurrence and malignancy (22, 23). As recently  
50 reviewed and concluded by Zanello et al (23), "*women should not be denied the replacement  
51 therapy solely due to endometriosis*". Women with vasomotor symptoms, especially when  
52 they experience early or premature menopause may use hormonal treatment. The drug to be  
53 selected should be combined estrogen and progestogen unrelated to being surgically  
54  
55

1 menopausal or not, since estrogen only regimens may activate the residual endometriotic foci  
2 even in women after surgery for endometriosis. There are also some implicative reports on  
3 malignant transformation (24). If the surgical procedure is selected, hysterectomy and  
4 bilateral salpingo-oophorectomy and excision of the visible endometriotic foci should be  
5 preferred since the risk of recurrence is higher with suboptimal surgery(25). Another  
6 important point is that, if the woman with endometriosis needs tamoxifen treatment, the risk  
7 of malignant transformation should be considered (22).  
8  
9

### 10 **Asymptomatic patient in women with endometriosis after the age of 40**

11 We do not know the exact prevalence of asymptomatic endometriosis at any age. The  
12 management is also quite blurred for asymptomatic patients with endometriosis.  
13 Asymptomatic endometriosis may be found by chance via imaging methods –mainly by  
14 ultrasound-or during the operations for other reasons. Although in 1996, Eric J Thomas has  
15 suggested a challenging opinion of his own by writing *“Asymptomatic endometriosis is likely  
16 to be a physiological phenomenon of very limited relevance both physician and the patient.”*  
17 (26) and finished his paper by referring “an unidentified Edinburg physician’s quote *“It is a  
18 very very clever doctor who can make an asymptomatic patient feel better”*, there are some  
19 recent “warning” articles on asymptomatic patient with endometriosis. In their very recent  
20 retrospectively analyzed case series, Son JH et al (27) reported 50 women with ovarian clear  
21 cell carcinoma. Of those, 11 were women with asymptomatic endometrioma and being under  
22 regular gynecological examination. The authors suggested yearly close surveillance from the  
23 age mid30s in patients with asymptomatic endometrioma.  
24  
25  
26  
27  
28

### 29 **Adenomyosis in women after the age 40**

30 Although it has been thought that adenomyosis is a different disease from endometriosis,  
31 however it has been suggested that it might be a “variant” rather than a disease (28). As shown  
32 in figure 1, co-existence of adenomyosis and endometriosis as well as myoma is common. The  
33 presentation may be abnormal uterine bleeding, pelvic pain or fertility problems. At the age  
34 of 40 and above, management is similar to the one at fertile ages. If the uterus is to be  
35 preserved, GnRH-a suppression or progestogens (especially Levonogestrel intrauterine  
36 system) may be appropriate treatment modalities. There are also uterus-sparing novel surgical  
37 options to excise the adenomyotic tissue (29). Nevertheless, most women with adenomyosis  
38 after 40 presenting with pain or abnormal bleeding instead of fertility problems, thus total  
39 hysterectomy should be offered.  
40  
41  
42  
43

### 44 **CONCLUSION**

45 Management of endometriosis in women over 40 years of age is challenging. Infertility or pain  
46 may be the major problems, or even there may be asymptomatic endometrioma. We need  
47 more data on women with asymptomatic or accidentally found endometrioma. Treatment of  
48 fertility problems or pain should be accordingly. The accumulated data on atypical  
49 endometriosis leading to endometriosis associated malignancy should be remembered in  
50 those women, thus surgical management may be more liberally chosen.  
51  
52  
53  
54  
55

## REFERENCES

1. Witt BR, Barad DH. Management of endometriosis in women older than 40 years of age. *Obstet Gynecol Clin North Am* 1993;20: 349–63.
2. Guy JM. Edgar Haydon. General practitioner and radium pioneer. *J Med Biog.* 2009;17:127–134.
3. Haas D, Chvatal R, Reichert B, Renner S, Shebl O, Binder H, Wurm P, Oppelt P. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. *Arch Gynecol Obstet.* 2012;286(3):667-70.
4. Gylfason JT, Kristjansson KA, Sverrisdottir G, Jonsdottir K, Rafnsson V, Geirsson RT. Pelvic endometriosis diagnosed in an entire nation over 20 years. *Am J Epidemiol.* 2010 1;172(3):237-43.
5. Inceboz U. Endometriosis after menopause. *Womens Health (Lond).* 2015;11(5):711-5.
6. Ottolina J, Bartiromo L, Viganò P, Makieva S, Schimberni M, Candiani M. Does endometriosis influence the age of menopause? *Minerva Ginecol* 2018; 70(2): 171-77.
7. Yasui T, Hayashi K, Mizunuma H, Kubota T, Aso T, Matsumura T, Lee JS, Suzuki S. Association of endometriosis-related infertility with age at menopause. *Maturitas* 2011;69(3):279-83.
8. Morotti M, Remorgida V, Venturini PL, Ferrero S. Endometriosis in postmenopause: a single institution experience. *Arch Gynecol Obstet* 2012;286:1571-75.
9. Sampson JA. Endometrial adenocarcinoma of the ovary, arising in the endometrial tissue in that organ. *Arch Surg* 1925;10:1-72.
10. Vercellini P, Viganò P, Buggio L, Makieva S, Scarfone G, Cribiù FM, Parazzini F, Somigliana E. Perimenopausal management of ovarian endometriosis and associated cancer risk: When is medical or surgical treatment indicated? *Best Pract Res Clin Obstet Gynaecol.* 2018;51:151-168.
11. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. *Hum Pathol.* 1988;19(9):1080-4.
12. Gadducci A, Lanfredini N, Tana R. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. *Gynecol Endocrinol.* 2014; 30(9):612-7.
13. Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, Olsen JH, Møller L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. *Cancer Epidemiol Biomarkers Prev.* 2005;14(12):2929-35.
14. Kobayashi H. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. *Int J Clin Oncol.* 2009 ;1(5):378-82. doi: 10.1007/s10147-009-0931-2.
15. Murakami K, Kotani Y, Shiro Y, Takaya H, Nakai H, Matsumura N. Endometriosis-associated ovarian cancer occurs early during the follow-up of endometrial cysts. *Int J Clin Oncol.* 2019 Aug 31 doi: 10.1007/s10147-019-01536-5. [Epub ahead of print].

- 1 16. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms  
2 for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *J Ovarian Res.* 2019;  
3 27;12(1):28.
- 4 17. Oral E, Aydin O, Kumbak BA, Ilvan S, Yilmaz H, Tustas E, Bese T, Demirkiran F, Arvas M.  
5 Concomitant endometriosis in malignant and borderline ovarian tumors. *J*  
6 *ObstetGynaecol.* 2018;38(8):1104-9.
- 7  
8
- 9 18. Gemmel LC, Webster KE, Kirtley S, Vincent K, Zondervan KT; Becker CM. *HumanReprod*  
10 *Update* 2017, 23(4):481-500.
- 11
- 12 19. D'Hooghe TM, Debrock S, Hill JA, Meuleman C. Endometriosis and subfertility: is  
13 the relationship resolved? *Semin Reprod Med* 2003; 21(02) 243-254.
- 14
- 15 20. DeZiegler D, Pirtea P, Carbonnel M, Poulain M, Ciccinielli E, Bulletti C, Kostaras K,  
16 Kontopoulos G, Keefe D, Ayoubi JM. Assisted reproduction in Endometriosis. *Best*  
17 *ClinPracticeResearchClinMetab* 2019;33(1):47-59.
- 18
- 19 21. Greco E, Pellicano M, DiSpiezioSardo A, Scherillo A, Cerrota G, Bramante S, Nappi C.  
20 Etiopathogenesis of endometriosis related infertility. *Minerva Ginecol.* 2004;56(3):259-70.
- 21
- 22 22. Tan DA, Almira JG. Postmenopausal endometriosis: drawing a clearer clinical picture.  
23 *Climacteric* 2018;21(3): 249-55.
- 24
- 25 23. Alio L, Angioni S, Arena S, Bartiromo L, Bergamini V, Berlanda N, Bonanni V, Bonin C, Buggio  
26 L, Candiani M, Centini G, D'Alterio MN, De Stefano F, Di Cello A, Exacoustos C, Fedele L,  
27 Frattaruolo MP, Geraci E, Lavarini E, Lazzeri L, Luisi S, Maiorana A, Makieva S, Maneschi F,  
28 Martire F, Massarotti C, Mattei A, Muzii L, Ottolina J, Pagliardini L, Perandini A, Perelli F, Pino  
29 I, Porpora MG, Remorgida V, Scagnelli G, Seracchioli R, Solima E, Somigliana E, Sorrenti G,  
30 Ticino A, Venturella R, Viganò P, Vignali M, Zullo F, Zupi E. Endometriosis: seeking optimal  
31 management in women approaching menopause.  
32 *Climacteric.* 2019;22(4):329-338.
- 33
- 34 24. Zanello M, Borghese G, Manzara F, Degli Esposti E, Moro E, Raimondo D, Abdullahi LO,  
35 Arena A, Terzano P, Merigiola MC, Seracchioli R. Hormonal Replacement Therapy in  
36 Menopausal Women with History of Endometriosis: A Review of Literature. *Medicina*  
37 (Kaunas). 2019, 14;55(8). pii: E477.
- 38
- 39
- 40 25. Matorras R, Elorriaga MA, Pijoan JI, Ramón O, Rodríguez-Escudero FJ. Recurrence of  
41 endometriosis in women with bilateral adnexectomy (with or without total hysterectomy)  
42 who received hormone replacement therapy. *Fertil Steril.* 2002;77(2):303-8.
- 43
- 44 26. Thomas EJ. The relevance of endometriosis. *Hum Reprod* 1996, 11 (3):103-9.
- 45
- 46 27. Son JH, Yoon S, Kim S, Kong TW, Paek J, Chang SJ, Ryu HS. Clinicopathologic Characteristics  
47 of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy  
48 for an early detection of malignant transformation in patients with asymptomatic  
49 endometrioma. *Obstet GynecolSci,* 2019;62(1):27-34.
- 50
- 51 28. Weiss G, Maseelall P, Schott LL, Brockwell SE, Schocken M, Johnston JM. Adenomyosis a  
52 variant, not a disease? Evidence from hysterectomized menopausal women in the Study of  
53 Women's Health Across the Nation (SWAN). *Fertil Steril.* 2009 Jan;91(1):201-6.
- 54
- 55

1 29. Tan J, Yong P, Bedaiwy MA. A critical review of recent advances in the diagnosis,  
2 classification, and management of uterine adenomyosis. *Curr Opin Obstet Gynecol*. 2019  
3 Aug;31(4):212-221.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

PEER REVIEW COPY  
Minerva Medica




Figure 1: DRAGON's TRIANGLE

\*: co-prevalance rate

(Modified from the work of Prof Michel Mueller, Switzerland)

PEER REVIEW COPY  
Minerva Medica

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55




Figure 2: Algorithm for pain management for women with endometriosis over the age of 40.




Figure 3: Algorithm infertility management for women with endometriosis over the age of 40.

\*: "Surgery" should be chosen in the management of women with suspicious malignancy